Two scientists from Zaragoza, José Ramón Conejo-García and Carmen Anadón Galindo, have become an international scientific reference within a team of researchers from the Duke University School of Medicine, in North Carolina (United States), who placed at the forefront of research with their discoveries in the field of oncology and the search for more effective treatments to fight cancer.
Conejo-García, 57, has developed his entire career outside Spain, far from his native Calatayud. Until becoming a professor of immunology at Duke University, where he has worked for more than 20 years, this Aragonese traveled through Germany and Switzerland. An experience that gives him the perspective needed to advocate for greater investment in research in his native country: “Research here is another world. The figures and the money available have nothing to do with the situation in Spain. It is clear that for every dollar “What is allocated to research, its return is multiplied,” he assures the newspaper. Herald of Aragon.
For his part, Anadón Galindo, 32, crossed the Atlantic after passing through laboratories in Alcalá de Henares, Salamanca and Barcelona, where he specialized in biology and genetics. Also from Calatayud, this researcher has focused her career on the search for new therapeutic avenues that minimize the side effects of chemotherapy and radiotherapy in cancer patients. In fact, one of the latest studies that he signed and which has just appeared in the journal Immunity, “It has had a great impact in the field of oncology by detecting which type of antibodies help control the growth of tumors: it fills you, you see that there is a direct application to improve the lives of patients, but there is still a lot to do.”, also specifies in Herald of Aragon.
The published study, which included scientists from centers including the Moffitt Cancer Center & Research Institute and the Duke School of Medicine, shows how IgA antibodies can enter tumor cells and neutralize mutated oncoproteins, thereby controlling the growth of tumors. “The role played by IgA antibodies in tumors was not known,” Galindo emphasizes in the aforementioned journal, in which he explains that this discovery reduces the side effects of chemotherapy in cancer patients.